ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-1.09 Insider Own0.07% Shs Outstand156.67M Perf Week16.31%
Market Cap254.13M Forward P/E- EPS next Y-0.76 Insider Trans-39.15% Shs Float88.31M Perf Month-14.14%
Income-170.60M PEG- EPS next Q-0.25 Inst Own74.90% Short Float5.12% Perf Quarter-42.86%
Sales9.30M P/S27.33 EPS this Y-11.10% Inst Trans2.09% Short Ratio4.54 Perf Half Y-60.58%
Book/sh1.04 P/B1.58 EPS next Y-41.40% ROA-41.80% Target Price6.00 Perf Year-67.78%
Cash/sh1.96 P/C0.84 EPS next 5Y1.00% ROE-76.80% 52W Range1.26 - 6.86 Perf YTD-56.27%
Dividend- P/FCF- EPS past 5Y-0.10% ROI-79.10% 52W High-76.09% Beta2.11
Dividend %- Quick Ratio5.40 Sales past 5Y-15.40% Gross Margin- 52W Low30.16% ATR0.18
Employees494 Current Ratio5.40 Sales Q/Q800.00% Oper. Margin- RSI (14)47.10 Volatility12.87% 10.65%
OptionableYes Debt/Eq0.00 EPS Q/Q-31.80% Profit Margin- Rel Volume0.26 Prev Close1.67
ShortableYes LT Debt/Eq0.00 EarningsMay 09 BMO Payout- Avg Volume996.14K Price1.64
Recom2.70 SMA20-1.44% SMA50-12.98% SMA200-54.20% Volume263,161 Change-1.80%
May-28-21Initiated Barclays Underweight $4
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
May-17-22 05:03PM  
May-16-22 05:00PM  
May-09-22 07:30AM  
May-04-22 08:00AM  
Apr-28-22 04:30PM  
Apr-26-22 07:24AM  
Apr-22-22 09:03AM  
Apr-19-22 03:43PM  
Apr-11-22 04:40PM  
Apr-08-22 01:00PM  
Mar-25-22 07:18AM  
Mar-14-22 11:31AM  
08:00AM  
Mar-08-22 04:14PM  
12:36PM  
Mar-02-22 11:22AM  
11:16AM  
10:00AM  
Feb-24-22 02:49PM  
Feb-18-22 10:29AM  
10:15AM  
Feb-16-22 11:48AM  
Feb-15-22 12:03PM  
Feb-01-22 04:11AM  
Jan-26-22 08:00AM  
Jan-19-22 10:15AM  
Dec-30-21 06:52AM  
Dec-04-21 04:39PM  
Dec-03-21 04:25AM  
Dec-01-21 03:27PM  
Nov-18-21 10:00AM  
Nov-12-21 07:00AM  
Nov-11-21 09:00AM  
Nov-04-21 04:00PM  
07:30AM  
Oct-21-21 08:00AM  
Oct-16-21 07:00AM  
Oct-05-21 08:00AM  
Oct-04-21 06:09AM  
Sep-27-21 10:08AM  
Sep-24-21 08:52AM  
Sep-17-21 04:48PM  
Sep-13-21 09:50AM  
07:00AM  
Sep-08-21 11:39AM  
10:55AM  
Sep-07-21 02:32PM  
10:16AM  
09:08AM  
07:00AM  
03:52AM  
Sep-06-21 10:48AM  
Sep-05-21 06:15AM  
Aug-23-21 01:38PM  
Aug-16-21 10:05AM  
Aug-09-21 06:30PM  
04:00PM  
Aug-05-21 01:07AM  
Jul-28-21 08:11AM  
Jul-19-21 10:00AM  
Jun-21-21 10:00AM  
Jun-06-21 03:01AM  
May-20-21 05:49PM  
10:15AM  
May-19-21 05:00PM  
May-11-21 12:32PM  
08:00AM  
May-06-21 07:30AM  
Apr-27-21 04:30PM  
Apr-22-21 08:00AM  
Apr-07-21 01:09AM  
Feb-25-21 07:30AM  
06:15AM  
Feb-11-21 08:00AM  
Feb-06-21 01:03AM  
Dec-16-20 12:32PM  
Dec-07-20 11:32PM  
Nov-20-20 07:30AM  
Nov-19-20 09:00AM  
Nov-12-20 08:00AM  
Nov-09-20 03:18PM  
Nov-08-20 10:00AM  
Nov-06-20 11:01AM  
Nov-05-20 07:30AM  
06:15AM  
Oct-22-20 08:00AM  
Oct-16-20 12:41PM  
Oct-15-20 04:40PM  
Oct-13-20 12:04PM  
Oct-09-20 06:18AM  
Aug-28-20 10:30AM  
Aug-11-20 12:00PM  
Aug-10-20 07:40AM  
07:25AM  
Aug-06-20 07:30AM  
Jul-23-20 04:00PM  
Jul-22-20 08:00AM  
Jul-05-20 02:25PM  
Jun-23-20 11:26AM  
Jun-17-20 09:33AM  
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. to develop and commercialize allogeneic cell therapies to treat various oncology indications. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bertrand William C JRChief Operating OfficerJan 18Sale3.194,36813,9427,336Jan 18 09:04 PM
Lunger JohnChief Patient Supply OfficerJan 18Sale3.194,36813,9427,336Jan 18 09:03 PM
Norry ElliotChief Medical OfficerJan 18Sale3.192,1216,7703,529Jan 18 09:02 PM
Rawcliffe AdrianChief Executive OfficerJan 18Sale3.1911,09635,41612,312Jan 18 09:00 PM
Lunger JohnChief Patient Supply OfficerJan 12Sale3.541,0763,8131,749Jan 13 09:02 PM
Norry ElliotChief Medical OfficerJan 12Sale3.548543,0271,383Jan 13 09:01 PM
Rawcliffe AdrianChief Executive OfficerJan 12Sale3.543,04610,7953,356Jan 13 09:01 PM
Bertrand William C JRChief Operating OfficerJan 12Sale3.542,2487,9673,754Jan 13 09:02 PM
Bertrand William C JRChief Operating OfficerJan 11Sale3.563,77013,4096,343Jan 13 09:02 PM
Rawcliffe AdrianChief Executive OfficerJan 11Sale3.5614,36251,08115,978Jan 13 09:01 PM
Norry ElliotChief Medical OfficerJan 11Sale3.563,77013,4096,343Jan 13 09:01 PM
Lunger JohnChief Patient Supply OfficerJan 11Sale3.563,77013,4096,343Jan 13 09:02 PM
Bertrand William C JRChief Operating OfficerJan 04Sale4.063,49014,1845,873Jan 05 09:08 PM
Norry ElliotChief Medical OfficerJan 04Sale4.068493,4511,388Jan 05 09:05 PM
Lunger JohnChief Patient Supply OfficerJan 04Sale4.061,0704,3491,755Jan 05 09:06 PM
Rawcliffe AdrianChief Executive OfficerJan 04Sale4.065,53222,4836,172Jan 05 09:04 PM
Rawcliffe AdrianChief Executive OfficerSep 01Sale5.202,78214,4523,070Sep 01 09:00 PM
Lunger JohnChief Patient Supply OfficerAug 02Sale3.582,93910,5364,873Aug 02 05:09 PM
Rawcliffe AdrianChief Executive OfficerJun 28Sale4.372,79412,2103,058Jun 28 09:01 PM
Alleva Lawrence MDirectorJun 01Buy0.7912,6009,95412,600Jun 03 04:31 PM